(NASDAQ: MTSR) Metsera's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Metsera's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast MTSR's revenue for 2028 to be $5,778,054,590, with the lowest MTSR revenue forecast at $5,778,054,590, and the highest MTSR revenue forecast at $5,778,054,590. On average, 1 Wall Street analysts forecast MTSR's revenue for 2029 to be $41,391,881,972, with the lowest MTSR revenue forecast at $41,391,881,972, and the highest MTSR revenue forecast at $41,391,881,972.
In 2030, MTSR is forecast to generate $96,651,094,960 in revenue, with the lowest revenue forecast at $96,651,094,960 and the highest revenue forecast at $96,651,094,960.